0.03
—
Close of 9 Nov 2026, in NZD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rua Bioscience
Its shares trade on NZX under the ticker RUA.NZ. It has been listed since 22 October 2020. In the fiscal year to 30 June 2025, it reported revenue of NZD 1.5m and a net loss of NZD 3.5m. At that date it held total assets of NZD 6.8m and shareholders' equity of NZD 4.9m.
Rua Bioscience Ltd. operates as a pharmaceutical company that develops medical cannabis products. The company is headquartered in Gisborne, Gisborne. The company went IPO on 2020-10-22. The firm is engaged in the business of research and development, and pharmaceutical distribution and marketing. The firm is focused on breeding, cultivating, manufacturing, and supplying medicinal cannabis. The firm operates through one segment: research and development and the sale of pharmaceutical products in Germany and New Zealand. The firm also operates a full research laboratory in Gisborne, which enables cannabinoid testing, microscopic analysis, moisture analysis, sample preparation and extraction, solvent removal, viscosity measurements, and impurity testing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Oct 2020
- Website
- ruabio.com ↗
Leadership
Pay as last reported
- Ms. Anna StoveIndependent Chairman of the Board, since 2019
- Mr. Paul NaskeChief Executive Officer, Interim Managing Director
- Mr. Manu CaddieKaihautu Innovation & Regulation
- Mr. John SandersChief of Sales and Marketing, Australia
- Mr. Panapa EhauDirector
- Mr. Tony BarclayIndependent Non-Executive Director
- Ms. Teresa Farac- CiprianIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rua Bioscience develops medical cannabis products in Gisborne, New Zealand.
- The company operates a full research laboratory for cannabinoid testing and analysis.
- Rua Bioscience focuses on breeding, cultivating, and manufacturing medicinal cannabis in Germany and New Zealand.
Weaknesses
- Rua Bioscience's operations are limited to Germany and New Zealand markets.
- The company's business is solely focused on pharmaceutical distribution and marketing.
- Rua Bioscience has no presence in other countries or segments.
Opportunities
- Rua Bioscience can expand its research and development in the Health Care sector.
- The company may grow its pharmaceutical distribution in Germany and New Zealand.
- Rua Bioscience can leverage its laboratory capabilities for new product development.
Threats
- Rua Bioscience faces competition from other pharmaceutical companies in the Health Care sector.
- The company's reliance on medical cannabis may lead to regulatory challenges.
- Rua Bioscience's operations are restricted to two countries, limiting market reach.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.